Cargando…

HER2 as a potential therapeutic target on quiescent prostate cancer cells

Quiescent prostate cancer (PCa) cells are common in tumors but are often resistant to chemotherapy. Quiescent PCa cells are also enriched for a stem-like tumor initiating population, and can lead to recurrence after dormancy. Unfortunately, quiescent PCa cells are difficult to identify and / or targ...

Descripción completa

Detalles Bibliográficos
Autores principales: Yumoto, Kenji, Rashid, Jibraan, Ibrahim, Kristina G., Zielske, Steven P., Wang, Yu, Omi, Maiko, Decker, Ann M., Jung, Younghun, Sun, Dan, Remmer, Henriette A., Mishina, Yuji, Buttitta, Laura A., Taichman, Russell S., Cackowski, Frank C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9971552/
https://www.ncbi.nlm.nih.gov/pubmed/36805918
http://dx.doi.org/10.1016/j.tranon.2023.101642
Descripción
Sumario:Quiescent prostate cancer (PCa) cells are common in tumors but are often resistant to chemotherapy. Quiescent PCa cells are also enriched for a stem-like tumor initiating population, and can lead to recurrence after dormancy. Unfortunately, quiescent PCa cells are difficult to identify and / or target with treatment in part because the relevant markers are intracellular and regulated by protein stability. We addressed this problem by utilizing PCa cells expressing fluorescent markers for CDKN1B (p27) and CDT1, which can separate viable PCa cells into G(0), G(1), or combined S/G(2)/M populations. We used FACS to collect G(1) and G(0) PC3 PCa cells, isolated membrane proteins, and analyzed protein abundance in G(0) vs G(1) cells by gas chromatography mass spectrometry. Enrichment analysis identified nucleocytoplasmic transport as the most significantly different pathway. To identify cell surface proteins potentially identifying quiescent PCa cells for future patient samples or for antibody based therapeutic research, we focused on differentially abundant plasma membrane proteins, and identified ERBB2 (HER2) as a cell surface protein enriched on G(0) PCa cells. High HER2 on the cell membrane is associated with quiescence in PCa cells and likely induced by the bone microenvironment. Using a drug conjugated anti-HER2 antibody (trastuzumab emtansine) in a mouse PCa xenograft model delayed metastatic tumor growth, suggesting approaches that target HER2-high cells may be beneficial in treating PCa. We propose that HER2 is deserving of further study in PCa as a target on quiescent cells to prevent recurrence, decrease chemotherapy resistance, or eradicate minimal residual disease.